Literature DB >> 10740253

Matrix metalloproteinases: multifunctional contributors to tumor progression.

L J McCawley1, L M Matrisian.   

Abstract

Matrix metalloproteinases (MMPs) are a family of extracellular matrix degrading proteinases. Owing to their matrix-degrading abilities and high expression in advanced tumors, MMPs were originally implicated in invasion and metastasis during cancer progression. However, recent work extends a role for MMPs during multiple stages of tumor progression to include other functions such as growth, angiogenesis and migration. Based on studies in animal models implicating MMP activity in cancer, synthetic MMP inhibitors are currently being tested in a clinical setting.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10740253     DOI: 10.1016/s1357-4310(00)01686-5

Source DB:  PubMed          Journal:  Mol Med Today        ISSN: 1357-4310


  152 in total

Review 1.  Order and disorder: the role of extracellular matrix in epithelial cancer.

Authors:  Derek Radisky; John Muschler; Mina J Bissell
Journal:  Cancer Invest       Date:  2002       Impact factor: 2.176

2.  Molecular cloning and characterization of a matrix metalloproteinase, from Caenorhabditis elegans: employed to identify homologous protein from Angiostrongylus cantonensis.

Authors:  Rui Sun; Zheng-yu Li; Han-jiang He; Jie Wei; Juan Wang; Qi-xian Zhang; Jia Zhao; Xi-mei Zhan; Zhong-dao Wu
Journal:  Parasitol Res       Date:  2011-12-14       Impact factor: 2.289

Review 3.  Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.

Authors:  Klaus Maskos; Wolfram Bode
Journal:  Mol Biotechnol       Date:  2003-11       Impact factor: 2.695

4.  Expression and distribution of matrix metalloproteinases and their inhibitors in the human iris and ciliary body.

Authors:  J Lan; R K Kumar; N Di Girolamo; P McCluskey; D Wakefield
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

5.  In vitro and in vivo endochondral bone formation models allow identification of anti-angiogenic compounds.

Authors:  Gabri van der Pluijm; Martine Deckers; Bianca Sijmons; Henny de Groot; John Bird; Ruth Wills; Socrates Papapoulos; Andy Baxter; Clemens Löwik
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

6.  Enzyme-catalyzed gel proteolysis: an anomalous diffusion-controlled mechanism.

Authors:  G C Fadda; D Lairez; B Arrio; J-P Carton; V Larreta-Garde
Journal:  Biophys J       Date:  2003-11       Impact factor: 4.033

7.  Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone.

Authors:  Svetlana Mukhina; Hichem C Mertani; Ke Guo; Kok-Onn Lee; Peter D Gluckman; Peter E Lobie
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-07       Impact factor: 11.205

Review 8.  Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates.

Authors:  Xiao-Xiang Zhang; Henry S Eden; Xiaoyuan Chen
Journal:  J Control Release       Date:  2011-10-26       Impact factor: 9.776

9.  Matrix metalloproteinase inhibitor, MMI270 (CGS27023A) inhibited hematogenic metastasis of B16 melanoma cells in both experimental and spontaneous metastasis models.

Authors:  Tatsuhiko Kasaoka; Hiroko Nishiyama; Mikiko Okada; Motowo Nakajima
Journal:  Clin Exp Metastasis       Date:  2008-07-31       Impact factor: 5.150

10.  Expressions of matrix metalloproteinase-7 and -9 and their prognostic significances in rectal cancer.

Authors:  Young Rak Cho; Hyuk-Chan Kwon; Sung-Hwan Suh; Jong Hoon Lee; Sung-Hyun Kim; Hong-Jo Choi; Hyung-Sik Lee; Mee Sook Roh; Tae-Ho Hwang; Jae-Seok Kim; Hyo-Jin Kim
Journal:  Cancer Res Treat       Date:  2005-12-31       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.